Hairy cell leukemia: Update on molecular profiling and therapeutic advances

Blood Reviews

Volumn 28, Issue 5, 2014, Pages 197-203

  Grever, Michael R ^a,b   Blachly, James S ^a,b   Andritsos, Leslie A ^a,b  

^a Department of Internal Medicine Division of Hematology Ohio State University ^*  (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Hairy cell leukemia

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; CLADRIBINE; IBRUTINIB; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VACCINE; VEMURAFENIB;

ARTICLE; AUTOIMMUNE DISEASE; BRAF GENE; CANCER PROGNOSIS; CANCER RESISTANCE; GENE MUTATION; HAIRY CELL LEUKEMIA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPHENOTYPING; INFECTION PREVENTION; LEUKEMIA REMISSION; LONG TERM SURVIVAL; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SECOND CANCER; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; COMPLICATION; DISEASE MANAGEMENT; INFECTION; LEUKEMIA, HAIRY CELL; MEDICAL RESEARCH; MOLECULAR DIAGNOSIS;

BIOMEDICAL RESEARCH; DISEASE MANAGEMENT; HUMANS; IMMUNOPHENOTYPING; INFECTION; LEUKEMIA, HAIRY CELL; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84906937872     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.06.003     Document Type: Article

References (68)

1. Bouroncle B., Wiseman A.G., Doan C.A. Leukemic reticuloendotheliosis. Blood 1958, 13:609-630.
2. Chung S.S., Kim E., Park J.H., Chung Y.R., Lito P., Teruya-Feldstein J., et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 2014, 6:238ra71.
3. Clavel J., Mandereau L., Cordier S., Le Goaster C., Hemon D., Conso F., et al. Hairy cell leukaemia, occupation, and smoking. Br J Haematol 1995, 91:154-161.
4. Bouroncle B.A. Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 1979, 53:412-436.
5. Hoffman M.A. Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am 2006, 20:1065-1073.
6. Frassoldati A., Lamparelli T., Federico M., Annino L., Capnist G., Pagnucco G., et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma 1994, 13:307-316.
7. Grever M.R., Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol 2011, 29:583-590.
8. Rosenberg J.D., Burian C., Waalen J., Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 2014, 123:177-183.
9. Else M., Dearden C.E., Matutes E., Garcia-Talavera J., Rohatiner A.Z., Johnson S.A., et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16years from diagnosis. Br J Haematol 2009, 145:733-740.
10. Flinn I.W., Kopecky K.J., Foucar M.K., Head D., Bennett J.M., Hutchison R., et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000, 96:2981-2986.
11. Chadha P., Rademaker A.W., Mendiratta P., Kim B., Evanchuk D.M., Hakimian D., et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005, 106:241-246.
12. Johnston J.B., Eisenhauer E., Wainman N., Corbett W.E., Zaentz S.D., Daeninck P.J. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol 2000, 27:32-36.
13. Goodman G.R., Burian C., Koziol J.A., Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003, 21:891-896.
14. Wang X., Spielberger R., Huang Q. Hairy cell leukemia variant, a new entity of the WHO 2008. J Clin Oncol 2011, 29:e864-e866.
15. Robak T. Management of hairy cell leukemia variant. Leuk Lymphoma 2011, 52(Suppl. 2):53-56.
16. Shao H., Calvo K.R., Gronborg M., Tembhare P.R., Kreitman R.J., Stetler-Stevenson M., et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 2013, 37:401-409.
17. Kreitman R.J., Wilson W., Calvo K.R., Arons E., Roth L., Sapolsky J., et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res 2013, 19:6873-6881.
18. Summers T.A., Jaffe E.S. Hairy cell leukemia diagnostic criteria and differential diagnosis. Leuk Lymphoma 2011, 52(Suppl. 2):6-10.
19. Del Giudice I., Matutes E., Morilla R., Morilla A., Owusu-Ankomah K., Rafiq F., et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004, 89:303-308.
20. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M.P., et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011, 364:2305-2315.
21. Xi L., Arons E., Navarro W., Calvo K.R., Stetler-Stevenson M., Raffeld M., et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012, 119:3330-3332.
22. Andrulis M., Penzel R., Weichert W., von Deimling A., Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012, 36:1796-1800.
23. Akarca A.U., Shende V.H., Ramsay A.D., Diss T., Pane-Foix M., Rizvi H., et al. BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol 2013, 162:848-851.
24. Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol 2011, 29:55-66.
25. Forconi F., Sozzi E., Cencini E., Zaja F., Intermesoli T., Stelitano C., et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009, 114:4696-4702.
26. Waterfall J.J., Arons E., Walker R.L., Pineda M., Roth L., Killian J.K., et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014, 46:8-10.
27. Morrison V.A. Infections in patients with leukemia and lymphoma. Cancer Treat Res 2014, 161:319-349.
28. Burger J.A., Sivina M., Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma 2011, 52(Suppl. 2):94-98.
29. Bourguin-Plonquet A., Rouard H., Roudot-Thoraval F., Bellanger C., Marquet J., Delfau-Larue M.H., et al. Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia. Br J Haematol 2002, 116:595-597.
30. Netea M.G., Hoitink O., Kullberg B.J., van der Meer J.W., Raymakers R. Defective interferon-gamma production in patients with hairy cell leukaemia. Neth J Med 2008, 66:340-34.
31. Rice L., Shenkenberg T., Lynch E.C., Wheeler T.M. Granulomatous infections complicating hairy cell leukemia. Cancer 1982, 49:1924-1928.
32. Bastie J.N., Cazals-Hatem D., Daniel M.T., D'Agay M.F., Rabian C., Glaisner S., et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma 1999, 35:555-565.
33. Piro L.D., Carrera C.J., Carson D.A., Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990, 322:1117-1121.
34. Zenhausern R., Schmitz S.F., Solenthaler M., Heim D., Meyer-Monard S., Hess U., et al. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 2009, 50:1501-1511.
35. Robak T., Jamroziak K., Gora-Tybor J., Blonski J.Z., Kasznicki M., Dwilewicz-Trojaczek J., et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007, 109:3672-3675.
36. Saven A., Burian C., Adusumalli J., Koziol J.A. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999, 93:2471-2477.
37. Naik R.R., Saven A. My treatment approach to hairy cell leukemia. Mayo Clin Proc 2012, 87:67-76.
38. Grever M., Kopecky K., Foucar M.K., Head D., Bennett J.M., Hutchison R.E., et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995, 13:974-982.
39. Habermann T.M., Andersen J.W., Cassileth P.A., Bennett J.M., Oken M.M. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992, 80:466-471.
40. Habermann T.M. Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia. Hematol Oncol Clin North Am 2006, 20:1075-1086.
41. Johnston J.B. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma 2011, 52(Suppl. 2):43-45.
42. Kath R., Blumenstengel K., Fricke H.J., Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001, 127:48-54.
43. Mitsumori T., Sueki Y., Kawashima I., Yamamoto T., Nozaki Y., Nakajima K., et al. Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy. Rinsho Ketsueki 2014, 55:239-243.
44. Jones G., Parry-Jones N., Wilkins B., Else M., Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 2012, 156:186-195.
45. Tomblyn M., Chiller T., Einsele H., Gress R., Sepkowitz K., Storek J., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
46. van Assen S., Holvast A., Benne C.A., Posthumus M.D., van Leeuwen M.A., Voskuyl A.E., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
47. Teodorescu M., Engebjerg M.C., Johansen P., Norgaard M., Gregersen H. Incidence, risk of infection and survival of hairy cell leukaemia in Denmark. Dan Med Bull 2010, 57:A4216.
48. Grever M.R. How I, treat hairy cell leukemia. Blood 2010, 115:21-28.
49. Grever M.R. Hairy cell: young living longer but not cured. Blood 2014, 123:150-151.
50. Raimbourg J., Cormier G., Stephane V., Tanguy G., Bleher Y., Maisonneuve H. Hairy-cell leukemia with inaugural joint manifestations. Joint Bone Spine 2009, 76:416-420.
51. Hauswirth A.W., Skrabs C., Schutzinger C., Raderer M., Chott A., Valent P., et al. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica 2008, 93:447-450.
52. Hauswirth A.W., Skrabs C., Schutzinger C., Gaiger A., Lechner K., Jager U. Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk Lymphoma 2007, 48:1139-1149.
53. Dasanu C.A., Alexandrescu D.T. Risk of additional cancers in untreated and treated hairy cell leukemia patients. Expert Opin Pharmacother 2010, 11:41-50.
54. Hisada M., Chen B.E., Jaffe E.S., Travis L.B. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007, 99:215-222.
55. Pakneshan S., Salajegheh A., Smith R.A., Lam A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013, 45:346-356.
56. Saven A., Burian C., Koziol J.A., Piro L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998, 92:1918-1926.
57. Tallman M.S. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. Leuk Lymphoma 2011, 52(Suppl. 2):65-68.
58. Mhawech-Fauceglia P., Oberholzer M., Aschenafi S., Baur A., Kurrer M., Von Rohr A., et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 2006, 130:374-377.
59. Ravandi F., O'Brien S., Jorgensen J., Pierce S., Faderl S., Ferrajoli A., et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011, 118:3818-3823.
60. Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C.M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, 370:1101-1110.
61. Wayne A.S., Fitzgerald D.J., Kreitman R.J., Pastan I. Immunotoxins for leukemia. Blood 2014, 123:2470-2477.
62. Kreitman R.J., Tallman M.S., Robak T., Coutre S., Wilson W.H., Stetler-Stevenson M., et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012, 30:1822-1828.
63. Dietrich S., Glimm H., Andrulis M., von Kalle C., Ho A.D., Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012, 366:2038-2040.
64. Dietrich S., Hullein J., Hundemer M., Lehners N., Jethwa A., Capper D., et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 2013, 31:e300-e303.
65. Munoz J., Schlette E., Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 2013, 31:e351-e352.
66. Peyrade F., Re D., Ginet C., Gastaud L., Allegra M., Ballotti R., et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 2013, 98:e20-e22.
67. Tiacci E., Schiavoni G., Martelli M.P., Boveri E., Pacini R., Tabarrini A., et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica 2013, 98:635-639.
68. Samuel J., Macip S., Dyer M.J. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014, 370:286-288.